Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Recruiting PHASE2 INTERVENTIONAL NCT07224438

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.

Detailed Description

Assignment: All study subjects will undergo the same interventions. Delivery of Interventions: * The subject will undergo a review of their medical history, physical exam, and screening laboratories. * A pelvic ultrasound will be performed to assess baseline follicular size. * A pump will be placed to administer pulsatile SC kisspeptin for two weeks. * During the course of kisspeptin administration, subjects will * Undergo q10 min blood sampling (approximately 4 sessions, 2 hours each) * Undergo pelvic ultrasounds (approximately 4 sessions) * Optional q10 min sampling up to 10 hours may take place before and after the course of kisspeptin

Interventions

Name: kisspeptin 112-121
Type: DRUG
Description: SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)

Primary Outcomes

Measure: Change of luteinizing hormone (LH) pulse amplitude
TimeFrame: 2 weeks
Description: Difference in LH amplitude on the first day of kisspeptin administration vs the last day of kisspeptin administration

Trial Information

NCT ID

NCT07224438

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE2

Sponsor

Stephanie B. Seminara, MD

Last Updated

December 15, 2025